Skip to main content

Table 2 Logistic regression analysis to identify factors associated with MRA prescription

From: Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction

  

Eligible

 

Ineligible

 
  

OR (95 % CI)

Adjusted p-value

OR (95 % CI)

Adjusted p-value

Demographics

Age

1.01 (0.98–1.03)

0.69

1.00 (0.98–1.02)

0.91

Female

0.97 (0.51–1.83)

0.92

2.22 (1.27–3.88)

0.01

Length of stay

1.01 (0.99–1.02)

0.33

1.01 (0.99–1.03)

0.17

Medical history

Heart failure

1.66 (0.83–3.32)

0.15

2.38 (0.97–5.85)

0.06

Hypertension

0.99 (0.56–1.75)

0.97

1.24 (0.70–2.17)

0.46

Dyslipidemia

0.47 (0.26–0.85)

0.01

0.73 (0.41–1.29)

0.40

Diabetes

1.06 (0.61–1.83)

0.84

1.33 (0.69–2.56)

0.28

Smoking

1.84 (1.03–3.27)

0.04

1.39 (0.81–2.39)

0.23

MI

0.99 (0.50–1.95)

0.98

1.05 (0.54–2.03)

0.89

Clinical data

SBP

0.99 (0.97–1.00)

0.16

1.00 (0.99–1.01)

0.58

Heart rate

1.01 (0.99–1.03)

0.17

0.99 (0.97–1.01)

0.40

LVEF

0.93 (0.90–0.97)

0.00

0.93 (0.90–0.96)

0.00

STEMI

1.44 (0.74–2.80)

0.28

1.62 (0.85–3.10)

0.15

Laboratory data

Troponin T

1.02 (0.97–1.07)

0.39

1.05 (1.00–1.09)

0.05

Potassium

0.50 (0.23–1.08)

0.08

1.01 (0.56–1.79)

0.99

Estimated GFR

1.00 (0.99–1.01)

0.87

1.00 (0.99–1.01)

0.74

  1. Analysis of factors associated with increased rates of MRA prescription. CI, confidence interval; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; μg/L, micrograms per liter; μmol/L, micromole per liter; mmHg, millimeters mercury; mmol/L, millimoles per liter; OR, odds ratio; STEMI, ST elevation myocardial infarction; SBP, systolic blood pressure
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us